Sign Up Today and Learn More About XyloCor Therapeutics Stock
Invest in or calculate the value of your shares in XyloCor Therapeutics or other pre-IPO companies through EquityZen's platform.
XyloCor Therapeutics Stock (XYTH)
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease.
About XyloCor Therapeutics Stock
Founded
2013
Headquarters
Wayne, PA, US
Industries
Science and Engineering, Health Care, Biotechnology
XyloCor Therapeutics Press Mentions
Stay in the know about the latest news on XyloCor Therapeutics
STAT+: Up and down the ladder: The latest comings and goings
statnews • Apr 12, 2025
Biopharmaceuticals Market Size Expected to Reach USD 1,796.21 Bn by 2034
biospace • Feb 17, 2025
Philly Startup Funding Shows Eagles-Like Strength
news • Feb 07, 2025
5 Cardio Gene Therapies on the Near Horizon
biospace • Jan 13, 2025
XyloCor Therapeutics Raises $67.5M in Series B Financing
finsmes • Jan 08, 2025
XyloCor Therapeutics Management
Leadership team at XyloCor Therapeutics
Director of Operations and Finance
Jennifer Augusti
President and CEO
Albert Gianchetti
Join now and verify your accreditation status to gain access to:
- XyloCor Therapeutics Current Valuation
- XyloCor Therapeutics Stock Price
- XyloCor Therapeutics Management
- Available deals in XyloCor Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- XyloCor Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- XyloCor Therapeutics Revenue and Financials
- XyloCor Therapeutics Highlights
- XyloCor Therapeutics Business Model
- XyloCor Therapeutics Risk Factors
- XyloCor Therapeutics Research Report from SACRA Research
Trading XyloCor Therapeutics Stock
How to invest in XyloCor Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like XyloCor Therapeutics through EquityZen funds. These investments are made available by existing XyloCor Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell XyloCor Therapeutics stock?
Shareholders can sell their XyloCor Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
